🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Hangzhou Highlightll Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Hangzhou Highlightll Pharmaceutical as lead sponsor. Synced 26 Sep 2026
7Current trials
2Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Hangzhou Highlightll Pharmaceutical is the lead sponsor of 7 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are TLL-018 and Tofacitinib. The most-studied condition is Rheumatoid Arthritis.

ClinicalTrials.gov trials by status

  • Recruiting229%
  • Not yet open343%
  • Active, closed229%

Trials by phase

  • Phase 3343%
  • Phase 1/2229%
  • Phase 2114%
  • Phase 2/3114%
01

Clinical trials sponsored by Hangzhou Highlightll Pharmaceutical

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
NCT07629778 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Phase 1/2 Recruiting 2026-05 China
A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis
NCT06887127 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis
Drug: TLL-018
Phase 3 Recruiting 2025-03 China
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
NCT07748728 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA)
Drug: TLL-018
Phase 2 Not yet open 2026-08 China
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07784816 · ClinicalTrials.gov ↗ · Atopic Dermatitis (AD)
Drug: TLL-018
Phase 2/3 Not yet open 2026-08 China
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
NCT07665996 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria (CSU)
Drug: TLL-018
Phase 1/2 Not yet open 2026-08 China
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
NCT06020144 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis
Phase 3 Active, closed 2023-11 China
A Study of Efficacy and Safety of TLL-018 in CSU Participants
NCT06396026 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria
Drug: TLL-018
Phase 3 Active, closed 2024-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Hangzhou Highlightll Pharmaceutical trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Hangzhou Highlightll Pharmaceutical trials

6 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China72

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Rheumatoid Arthritis

SponsorTrials
Zimmer Biomet13
SetPoint Medical Corporation2
Alfasigma1
Immunovant Sciences1
Medacta International1
Sonoma Biotherapeutics1
Shenzhen MagicRNA Biotechnology1

Sponsors with the most current trials registered for this condition.

06

Questions about Hangzhou Highlightll Pharmaceutical trials

How many clinical trials does Hangzhou Highlightll Pharmaceutical sponsor?

Hangzhou Highlightll Pharmaceutical is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hangzhou Highlightll Pharmaceutical trials recruiting?

Yes. 2 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hangzhou Highlightll Pharmaceutical testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are TLL-018 (6) and Tofacitinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.